Painuli, SakshiSemwal, PrabhakarZam, WissamTaheri, YasamanEzzat, Shahira MZuo, PeijunLi, LipingKumar, DileepSharifi-Rad, JavadCruz-Martins, Natália2023-03-062023-03-062023-0310.2174/1386207325666220428112541http://repository.msa.edu.eg/xmlui/handle/123456789/5411Alzheimer’s disease (AD) is an increasingly common neurodegenerative disease that at- tracts the attention of researchers and medical community in order to develop new, safe and more effective drugs. Currently available drugs could only slow the AD progression and relieve the symptoms, in addition to being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists were reported to have the ability to block the glutamate-mediated excitotoxic activity being good therapeutic targets for several neurodegenerative diseases, includ- ing AD. Based on data obtained so far, this review provides an overview over the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects regarding the use of NMDA antagonists for AD, and lastly a key focus is also given on its use in precision medicine.en-USAlzheimer’s disease,neurodegeneration,N-methyl D-aspartate (NMDA) receptorsprecision medicineArticlehttps://doi.org/10.2174/1386207325666220428112541